Based on the positive relationship between depression and glucose metabolism, DEXA administration was found to induce MDD-like pathology through high glucose metabolism associated with increased expression of GLUT1 and GLUT3, along with increased levels of hexokinase and pyruvate kinase in the brain. This evidence concerns the gene SLC2A3 and depressive symptom measurement.